Altogether, our results indicate that ATRA-induced cellular differentiation blocks BCR-ABL mutation acquisition in CML cells, in which CD38 activation appears to play an important role by reducing cellular NAD+ content and thus inhibiting SIRT1 activity. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.